Results 91 to 100 of about 34,120 (225)
Movement Disorders Clinical Practice, EarlyView.Abstract Background α‐synuclein seeding amplification assay (α‐synuclein SAA) development as a diagnostic biomarker for Parkinson's disease (PD) has shown promising results over the past decade. However, the utility of these assays in the prediction of disease progression is unclear.
Daniel Belete +5 more
wiley +1 more source
The study of interaction of modified fatty acid with {99m}Tc in alcoholic media [PDF]
, 2016 The paper presents the results of laboratory research aimed at the development of methods of synthesis of new radiodiagnostic agents based on modified fatty acid labelled with technetium-99m intended for scintigraphic evaluation of myocardial metabolism.
Ilina, Elena Sergeevna +11 more
core +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background The Movement Disorder Society‐Unified Parkinson's Disease Rating Scale‐Part III (MDS‐UPDRS‐III) is subjective and insensitive to subtle changes in patients with Parkinson's disease (PD). Computer vision (CV) can extract objective kinematics from routine outpatient videos, potentially augmenting the accuracy of the motor assessment ...
Pasquale Maria Pecoraro +12 more
wiley +1 more source
The Reevaluation of MIBI as the Ligand of 99mTc-MIBI Radiopharmaceutical for Myocardial Imaging [PDF]
, 2008 Methoxy isobutyl isonitrile labelled with technetium-99m (99mTc) radionuclide can be used for the evaluation of acute myocardial infarction. The 99mTc-MIBI radiopharmaceutical is available in the lyophilized-kit, which is separately packed with its ...
Daruwati, I. (I), Nurlaila, Z. (Z)
core +2 more sources
Movement Disorders, EarlyView.Abstract Background Parkinson's disease (PD) is characterized by predominantly neuronal α‐synuclein pathology and dopaminergic dysfunction. Cerebrospinal fluid (CSF) seeding amplification assays (SAA) detect α‐synuclein aggregates in vivo, but not all patients with PD have a positive SAA.
Michael Tran Duong +186 more
wiley +1 more source
Scalability study on [133La]LaCl3 production with a focus on potential clinical applications
EJNMMI Radiopharmacy and ChemistryBackground In recent years, targeted alpha therapy has gained importance in the clinics, and in particular, the alpha-emitter 225Ac plays a fundamental role in this clinical development.
Santiago Andrés Brühlmann +6 more
doaj +1 more source
Development and Study of {99m}Tc-1-Thio-D-glucose for Visualization of Malignant Tumors [PDF]
, 2017 The preclinical studies of {99m}Tc-1-Thio-D-glucose, a new tumor-seeking agent based on technetium-99mlabeled glucose derivative, were conducted, and the feasibility of using this radiopharmaceutical for tumor visualization was studied.
Bragina, Olga Dmitrievna +8 more
core +1 more source
Movement Disorders, EarlyView.Abstract Background The cerebrospinal fluid alpha‐synuclein seed amplification assay (CSFasynSAA) detects alpha‐synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined.
Sarah M. Brooker +30 more
wiley +1 more source
Early Autonomic Burden in Prodromal Parkinson's Disease Predicts Cognitive Impairment
Movement Disorders, EarlyView.Abstract Background Autonomic dysfunction is a known contributor to cognitive impairment in Parkinson's disease (PD), but its impact during prodromal stage is unknown. Objective The aim was to determine whether early autonomic burden predicts incident cognitive impairment in prodromal PD.
A. Enrique Martinez‐Nunez +5 more
wiley +1 more source